Covid19 – Pfizer to start large study to test vaccine in children below 12
Pfizer Inc said on Tuesday it will start a large study to test its Covid-19 vaccine in children below 12 and selected a dosing regime for the trial. The study will enroll up to 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain, the company said.
Pfizer’s vaccine has been authorised for use in children as young as 12 in Europe, the United States and Canada. The company said it has selected a dose of 10 micrograms in children between 5 and 11 years of age and 3 micrograms between for infants in age-group of 6 months to five.
The UK has also approved Pfizer/BoiNTech coronavirus vaccine for use in children aged between 12 and 15 years. Data from clinical trials “is really showing that the vaccine is highly preventative” for young people. Pfizer and its partner BioNTech said in March that their two-dose vaccine regimen was shown to be safe and highly effective in a trial of 2,260 12- to 15-year-olds.
Singapore – The expert committee on Covid-19 vaccination continues to endorse the effectiveness of the mRNA-based Pfizer-BioNTech and Moderna vaccines used in Singapore, it said. The committee said it is aware of messages that are being disseminated on social media that claim that mRNA-based vaccines are ineffective against new variants of concern, and that vaccines that use an inactivated virus would provide superior protection.